Scenarios that move MYGN

Myriad Genetics, Inc. - Common Stock

Scenarios that move MYGN: 2 analyses, 0 positive, 2 negative.

1. 2026-10-16 · OPKO Health to sell BioReference assets to Labcorp for $722M — ▼ · impact -16 · confidence low · horizon quarters
2. 2026-09-21 · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▼ · impact -12 · confidence low · horizon quarters

All scenarios · Run a scenario · Pricing